Loading
A phase 1/2 trial of Nivolumab and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06697197 by Bristol-Myers Squibb, with 413 participants planned, started 2025-02-17 and due to reach its primary completion in 2029-01-04. Interventions recorded: BMS-986482, Nivolumab and rHuPH20, Nivolumab/relatlimab/rHuPH20 and Bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/